Annual Total Liabilities
$8.34 M
-$9.67 M-53.70%
December 31, 2023
Summary
- As of February 22, 2025, CMPX annual total liabilities is $8.34 million, with the most recent change of -$9.67 million (-53.70%) on December 31, 2023.
- During the last 3 years, CMPX annual total liabilities has fallen by -$3.63 million (-30.33%).
- CMPX annual total liabilities is now -94.42% below its all-time high of $149.40 million, reached on December 1, 2018.
Performance
CMPX Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$10.75 M
+$1.25 M+13.11%
September 1, 2024
Summary
- As of February 22, 2025, CMPX quarterly total liabilities is $10.75 million, with the most recent change of +$1.25 million (+13.11%) on September 1, 2024.
- Over the past year, CMPX quarterly total liabilities has increased by +$6.67 million (+163.42%).
- CMPX quarterly total liabilities is now -92.78% below its all-time high of $148.98 million, reached on December 1, 2019.
Performance
CMPX Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
CMPX Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -53.7% | +163.4% |
| 3 y3 years | -30.3% | +163.4% |
| 5 y5 years | -94.4% | +163.4% |
CMPX Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -53.7% | at low | -40.3% | +163.4% |
| 5 y | 5-year | -94.4% | at low | -92.8% | +163.4% |
| alltime | all time | -94.4% | at low | -92.8% | +163.4% |
Compass Therapeutics Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $10.75 M(+13.1%) |
| Jun 2024 | - | $9.51 M(+132.9%) |
| Mar 2024 | - | $4.08 M(-51.0%) |
| Dec 2023 | $8.34 M(-53.7%) | $8.34 M(-16.6%) |
| Sep 2023 | - | $9.99 M(-8.3%) |
| Jun 2023 | - | $10.89 M(-14.3%) |
| Mar 2023 | - | $12.71 M(-29.4%) |
| Dec 2022 | $18.01 M | $18.01 M(+53.6%) |
| Sep 2022 | - | $11.72 M(-12.0%) |
| Jun 2022 | - | $13.33 M(+10.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | $12.07 M(-11.7%) |
| Dec 2021 | $13.68 M(+14.3%) | - |
| Dec 2021 | - | $13.68 M(+24.2%) |
| Sep 2021 | - | $11.01 M(-8.2%) |
| Jun 2021 | - | $12.00 M(-18.5%) |
| Mar 2021 | - | $14.73 M(+23.1%) |
| Dec 2020 | $11.97 M(-92.0%) | $11.97 M(-10.7%) |
| Sep 2020 | - | $13.40 M(-22.1%) |
| Jun 2020 | - | $17.20 M(-88.5%) |
| Dec 2019 | $148.98 M(-0.3%) | $148.98 M |
| Dec 2018 | $149.40 M | - |
FAQ
- What is Compass Therapeutics annual total liabilities?
- What is the all time high annual total liabilities for Compass Therapeutics?
- What is Compass Therapeutics annual total liabilities year-on-year change?
- What is Compass Therapeutics quarterly total liabilities?
- What is the all time high quarterly total liabilities for Compass Therapeutics?
- What is Compass Therapeutics quarterly total liabilities year-on-year change?
What is Compass Therapeutics annual total liabilities?
The current annual total liabilities of CMPX is $8.34 M
What is the all time high annual total liabilities for Compass Therapeutics?
Compass Therapeutics all-time high annual total liabilities is $149.40 M
What is Compass Therapeutics annual total liabilities year-on-year change?
Over the past year, CMPX annual total liabilities has changed by -$9.67 M (-53.70%)
What is Compass Therapeutics quarterly total liabilities?
The current quarterly total liabilities of CMPX is $10.75 M
What is the all time high quarterly total liabilities for Compass Therapeutics?
Compass Therapeutics all-time high quarterly total liabilities is $148.98 M
What is Compass Therapeutics quarterly total liabilities year-on-year change?
Over the past year, CMPX quarterly total liabilities has changed by +$6.67 M (+163.42%)